» Articles » PMID: 36073846

Transcript Engineered Extracellular Vesicles Alleviate Alloreactive Dynamics in Renal Transplantation

Overview
Journal Adv Sci (Weinh)
Date 2022 Sep 8
PMID 36073846
Authors
Affiliations
Soon will be listed here.
Abstract

Direct contact of membrane molecules and cytokine interactions orchestrate immune homeostasis. However, overcoming the threshold of distance and velocity barriers, and achieving adhesion mediated immune interaction remain difficult. Here, inspired by the natural chemotaxis of regulatory T cells, multifunctionalized FOXP3 genetic engineered extracellular vesicles, termed Foe-TEVs, are designed, which display with adhesive molecules, regulatory cytokines, and coinhibitory contact molecules involving CTLA-4 and PD-1, by limited exogenous gene transduction. Foe-TEVs effectively adhere to the tubular, endothelial, and glomerular regions of allogeneic injury in the renal allograft, mitigating cell death in situ and chronic fibrosis transition. Remarkably, transcript engineering reverses the tracking velocity of vesicles to a retained phenotype and enhanced arrest coefficient by a factor of 2.16, directly interacting and attenuating excessive allosensitization kinetics in adaptive lymphoid organs. In murine allogeneic transplantation, immune adhesive Foe-TEVs alleviate pathological responses, restore renal function with well ordered ultrastructure and improved glomerular filtration rate, and prolong the survival period of the recipient from 30.16 to 92.81 days, demonstrating that the delivery of extracellular vesicles, genetically engineered for immune adhesive, is a promising strategy for the treatment of graft rejection.

Citing Articles

Injectable Genetic Engineering Hydrogel for Promoting Spatial Tolerance of Transplanted Kidney in Situ.

Lin J, Liu S, Xue X, Lv J, Zhao L, Yu L Adv Sci (Weinh). 2024; 11(48):e2408631.

PMID: 39498870 PMC: 11672315. DOI: 10.1002/advs.202408631.


Frontier role of extracellular vesicles in kidney disease.

Li B, Qi C, Zhang Y, Shi L, Zhang J, Qian H J Nanobiotechnology. 2024; 22(1):583.

PMID: 39304945 PMC: 11414213. DOI: 10.1186/s12951-024-02852-3.


Unlocking Transplant Tolerance with Biomaterials.

Pham J, Coronel M Adv Healthc Mater. 2024; 14(5):e2400965.

PMID: 38843866 PMC: 11834385. DOI: 10.1002/adhm.202400965.


Immunosuppressive microvesicles-mimetic derived from tolerant dendritic cells to target T-lymphocytes for inflammation diseases therapy.

Lin M, Lei S, Chai Y, Xu J, Wang Y, Wu C J Nanobiotechnology. 2024; 22(1):201.

PMID: 38659058 PMC: 11040880. DOI: 10.1186/s12951-024-02470-z.


Targeting Macrophages in Organ Transplantation: A Step Toward Personalized Medicine.

Owen M, Kopecky B Transplantation. 2024; 108(10):2045-2056.

PMID: 38467591 PMC: 11390981. DOI: 10.1097/TP.0000000000004978.


References
1.
Zarjou A, Guo L, Sanders P, Mannon R, Agarwal A, George J . A reproducible mouse model of chronic allograft nephropathy with vasculopathy. Kidney Int. 2012; 82(11):1231-5. PMC: 3495090. DOI: 10.1038/ki.2012.277. View

2.
Vietzen H, Dohler B, Tran T, Susal C, Halloran P, Eskandary F . Deletion of the Natural Killer Cell Receptor NKG2C Encoding Gene and Kidney Transplant Outcome. Front Immunol. 2022; 13:829228. PMC: 8987017. DOI: 10.3389/fimmu.2022.829228. View

3.
Kikic Z, Kainz A, Kozakowski N, Oberbauer R, Regele H, Bond G . Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection. Clin J Am Soc Nephrol. 2015; 10(8):1435-43. PMC: 4527028. DOI: 10.2215/CJN.09901014. View

4.
Wang S, Jiang J, Guan Q, Lan Z, Wang H, Nguan C . Reduction of Foxp3-expressing regulatory T cell infiltrates during the progression of renal allograft rejection in a mouse model. Transpl Immunol. 2008; 19(2):93-102. DOI: 10.1016/j.trim.2008.03.004. View

5.
Jakociunas T, Bonde I, Herrgard M, Harrison S, Kristensen M, Pedersen L . Multiplex metabolic pathway engineering using CRISPR/Cas9 in Saccharomyces cerevisiae. Metab Eng. 2015; 28:213-222. DOI: 10.1016/j.ymben.2015.01.008. View